ADMA Biologics Faces Securities Fraud Lawsuit Over Channel Stuffing Allegations; Lead Plaintiff Deadline August 10
ADMA sits 27% above its 52-week low of $7.21.
Summary
A securities fraud class action lawsuit has been filed against ADMA Biologics and its senior executives, alleging a channel stuffing scheme in 2025 to inflate revenue growth for its ASCENIV product. Investors have until August 10, 2026, to apply to be lead plaintiff. This follows news on June 30, 2026, that a class action lawsuit had been filed, stemming from a March 24, 2026, Culper Research report that caused ADMA's stock to drop significantly. The lawsuit formalizes serious allegations of financial misrepresentation, potentially leading to significant legal costs and reputational damage for the company.
At the time of this announcement, ADMA was trading at $9.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $7.21 to $20.46. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.